Summary
We investigated expression of a human p53-inducible gene, P2XM, a member of the P2X-receptor family of ATP-gated ion channels, in 56 human primary soft-tissue tumours including 47 sarcomas and nine benign tumors. Among the 47 sarcomas examined by reverse transcription polymerase chain reaction, 12 had lost expression of this gene and 22 revealed altered splicing patterns; among the nine benign tumours, four showed no expression of P2XM and three revealed aberrant splicing patterns involving transmembrane domains M1 and/or M2. As the aberrant transcripts lacked either or both of those domains, the protein products probably lacked normal function. We also looked for p53 mutations and mdm2 overexpression in the same panel of tumours and found them in 13 tumours, all but three of which had shown altered expression of P2XM. However, 31 (72%) of the 43 tumours that carried wild-type p53 without mdm2 overexpression had revealed aberrant P2XM expression. Our results suggest that disorder of P2XM expression may play a crucial role in the genesis of benign and malignant tumours in soft tissues, and that one or more genetic factors other than p53 or mdm2 contribute significantly to aberrant P2XM expression.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Andreassen, A., Oyjord, T., Hovig, E., Holm, R., Florenes, V. A., Nesland, J. M., Myklebost, O. & Hoie, J. (1993). p53 abnormalities in different sub-types of human sarcomas. Cancer Res 53: 468–471.
Buckbinder, L., Talbott, R., Velasco, M. S., Takenaka, I., Faha, B., Seizinger, B. R. & Kley, N. (1995). Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646–649.
Castresana, J. S., Barrios, C., Gómez, L. & Kreicbergs, A. (1994). No association between c-myc amplification and tp53 mutation in sarcoma tumorigenesis. Cancer Genet Cytogenet 76: 47–49.
Castresana, J. S., Rubio, M-P, Gómez, L., Kreicbergs, A., Zetterberg, A. & Barrios, C. (1995). Detection of tp53 gene mutations in human sarcomas. Eur J Cancer 31A: 735–738.
Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F. & Levine, A. J. (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794–799.
EI-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. & Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
Enjoji, M. & Hashimoto, H. (1984). Diagnosis of soft-tissue sarcomas. Pathol Res Pract 178: 215–226.
Enzinger, F. M., Lattes, R. & Torloni, R. (1969). Histologic typing of soft-tissue tumors. International classification of tumors 3: WHO: Geneva
Felix, C. A., Kappel, C. C., Mitsudomi, T., Nau, M. M., Tsokos, M., Crouch, G. D., Nisen, P. D., Winick, N. J. & Helman, I. J. (1992). Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 52: 2243–2247.
Furuhata, T., Tokino, T., Urano, T. & Nakamura, Y. (1996). Isolation of a novel GPI-anchored gene specifically regulated by p53; correlation between its expression and anticancer drug sensitivity. Oncogene 13: 1965–1970.
Haupt, Y., Maya, R., Kazaz, A. & Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387: 296–9.
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B. & Fornace, A. J. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597.
Kubbutat, M. H., Jones, S. N. & Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. Nature 387: 299–303.
Latres, E., Drobnjak, M., Pollack, D., Oliva, M. R., Ramos, M., Karpeh, M., Woodruff, J. M. & Cordon-Cardo, C. (1994). Chromosome-17 abnormalities and tp53 mutations in adult soft-tissue sarcoma. Am J Pathol 145: 345–355.
Leach, F. S., Tokino, T., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W. & Vogelstein, B. (1993). p53 mutations and mdm2 amplification in human soft-tissue sarcomas. Cancer Res 53: 2231–2234.
Masuda, H., Miller, C., Koeffler, H., Battifora, H. & Cline, M. (1987). Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84: 7716–7719.
Miyashita, T. & Reed, J. C. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293–299.
Morris, G. E., Bischoff, J. R. & Mathews, M. B. (1996). Transcriptional activation of the human proliferating cell nuclear antigen promoter by p53. Proc Natl Acad Sci USA 93: 895–899.
Okamoto, K. & Beach, D. (1994). Cyclin G is a transcriptional target of p53 tumor suppressor protein. EMBO J 13: 4816–4822.
Oliner, J. D., Kinzler, K. W., Meltzler, P. S., George, D. L. & Vogelstein, B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80–83.
Owens, G. P., Hahn, W. E. & Cohen, J. J. (1991). Identification of mRNAs associated with programmed cell death in immature thymocytes. Mol Cel Biol 11: 4177–4188.
Schneider-Stock, R., Radig, K., Oda, Y., Mellin, W., Rys, J., Niezabitowski, A. & Roessner, A. (1997). p53 gene mutations in soft-tissue sarcomas – correlations with p53 immunohistochemistry and DNA ploidy. J Cancer Res Clin Oncol 123: 211–218.
Stratton, M. R., Moss, S., Warren, W., Patterson, H., Clark, J., Fisher, C., Fletcher, C., Ball, A., Thomas, M., Gusterson, B. & Cooper, C. (1990). Mutation of the p53 gene in human soft-tissue sarcomas: association with abnormalities of the Rb1 gene. Oncogene 5: 1297–1301.
Taubert, H., Würl, P., Meye, A., Berger, D., Thamm, B., Neumann, K., Hinze, R., Schmidt, H. & Rath, F. W. (1995). Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Cancer 76: 1187–1195.
Taubert, H., Meye, A. & Würl, P. (1996). Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 56: 4134–4136.
Toguchida, J., Yamaguchi, T., Ritchie, B., Beauchamp, R. L., Dayton, S. H. & Herrera, G. E. (1992). Mutation spectrum of the p53 gene in bone and soft-tissue sarcomas. Cancer Res 52: 6194–6199.
Urano, T., Nishimori, H., Han, H., Furuhata, T., Kimura, Y., Nakamura, Y. & Tokino, T. (1997). Cloning of P2XM, a novel human P2X receptor gene regulated by p53. Cancer Res 57: 3281–3287.
Vogelstein, B. & Kinzler, K. W. (1992). p53 function and dysfunction. Cell 70: 523–526.
Wu, X., Bayle, J. H., Olson, D. & Levine, A. J. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Devel 7: 1126–1132.
Würl, P., Taubert, H., Bache, M., Kroll, J., Meye, A., Berger, D., Siermann, A., Holzhausen, H-J, Hinze, R., Schmidt, H. & Rath, F-W (1996). Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer 69: 317–323.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Nawa, G., Miyoshi, Y., Yoshikawa, H. et al. Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft-tissue tumours. Br J Cancer 80, 1185–1189 (1999). https://doi.org/10.1038/sj.bjc.6690484
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690484
Keywords
This article is cited by
-
Molecular and functional properties of P2X receptors—recent progress and persisting challenges
Purinergic Signalling (2012)
-
Determination of the architecture of ionotropic receptors using AFM imaging
Pflügers Archiv - European Journal of Physiology (2008)